Community Research and Development Information Service - CORDIS

Horizon 2020 project information and now also report summaries are available on CORDIS. All H2020 projects can be downloaded from the EU Open Data Portal .

My refinements


Download results of this page


Refine by:

Programme

FP7
All
FP7-JTI (21)

Language

English (21)

Advanced search

Results 1 - 10 of 21
Order by: Results/page:
12 3 > 
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
ID: 115620
Start date: 2015-03-01, End date: 2020-02-28
Multi-drug resistant Gram-negative bacteria (MDR-GNB): the ultimate challenge! Antibiotic resistance is a global public health concern recently elevated to the top three threats identified by the WHO, and subject of numerous national and international government activities. A...
Programme: FP7-JTI
Record Number: 203671
Last updated on: 2017-04-24
Combatting Bacterial Resistance in Europe
ID: 115523
Start date: 2013-01-01, End date: 2021-02-28
The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-At...
Programme: FP7-JTI
Record Number: 203711
Last updated on: 2017-04-24
Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk
ID: 115303
Start date: 2012-03-01, End date: 2017-11-30
The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia...
Programme: FP7-JTI
Record Number: 203697
Last updated on: 2017-04-17
New Models for Preclinical Evaluation of Drug Efficacy in Common Solid Tumours
ID: 115188
Start date: 2011-02-01, End date: 2016-04-30
Traditional preclinical discovery methods, particularly for target validation, poorly predict drug efficacy, causing a high attrition rate in costly late-stage clinical trials. The PREDECT consortium will focus on complex but transferable, next generation in vitro and in vivo...
Programme: FP7-JTI
Record Number: 203692
Last updated on: 2017-04-17
SAFER AND FASTER EVIDENCE-BASED TRANSLATION
ID: 115003
Start date: 2009-06-15, End date: 2015-06-14
The public-private consortium composed of complementary SMEs, academic and clinical centers of excellence and EMEA as partner proposes SAFE-T (Safer And Easter Evidence-based Iranslation) project for the establishment of a biomarker (BM) qualification process and its validati...
Programme: FP7-JTI
Record Number: 203675
Last updated on: 2017-04-17
Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC)
ID: 115439
Start date: 2012-10-01, End date: 2017-09-30
StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeuti...
Programme: FP7-JTI
Record Number: 203708
Last updated on: 2017-04-03
Drug Disease Model Resources
[PROJECT] DDMORE - Drug Disease Model Resources
ID: 115156
Start date: 2011-03-01, End date: 2016-08-31
Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making. M&S facilitates the c...
Programme: FP7-JTI
Record Number: 203691
Last updated on: 2017-04-03
Novel Methods leading to New Medications in Depression and Schizophrenia
ID: 115008
Start date: 2009-09-01, End date: 2015-02-28
Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are few novel treatments. We think this is because of three major “bottle-necks”: a lack of etiologically-driven or pathophysiologically-acc...
Programme: FP7-JTI
Record Number: 203680
Last updated on: 2017-04-03
DRIVING RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE
ID: 115618
Start date: 2014-10-01, End date: 2017-09-30
Antimicrobial resistance (AMR) is widespread. Its global human and economic burden is tremendous and increasing annually. Yet today only a few pharmaceutical companies retain active antibacterial drug discovery programmes. While the elaboration of antibiotics with novel mecha...
Programme: FP7-JTI
Record Number: 203717
Last updated on: 2017-03-06
Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections
ID: 115737
Start date: 2015-01-01, End date: 2021-12-31
Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of multidrug resistant (MDR) Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa. There is an unmet medical need to prevent P....
Programme: FP7-JTI
Record Number: 203724
Last updated on: 2017-02-27
12 3 > 
List retrieved on: 2017-04-28
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top